Press Release

Seraxis Inc. announces a commercialization grant award from the Maryland Stem Cell Research Fund (MSCRF).

admin

May 11, 2017

About Seraxis, Inc.

Seraxis is a private biotechnology company launched in 2013 and located in Germantown, Maryland. The Seraxis mission is to develop a practical and potent cell replacement therapy for insulin-dependent diabetes.

Seraxis Inc. announces a commercialization grant award from the Maryland Stem Cell Research Fund (MSCRF).

About Seraxis, Inc.

Seraxis Inc. closed a Series B financing Round and enters into a collaboration with Medytox Inc.

Seraxis Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.

Related articles

Seraxis Announced Closing of $40M Series C Financing Round.

Seraxis’ manufacturing suite completes GMP quality system audit ahead of SR-02 IND filing and transplantation of pancreatic clusters to patients with Type 1 Diabetes.

Seraxis wins grant from Maryland Stem Cell Research Fund to accelerate development of allogenetically compatible pancreatic islet replacement therapy for functional cure of T1D.